VivoSeq
Oncology

Advanced Solid Cancers

2

Pipeline Programs↗

4

Active Trials↗

7

Companies Involved↗

Advanced Solid Cancers is an early-stage landscape with 2 programs across 7 companies. The most active players are Treadwell Therapeutics, Inc, Fresenius Kabi Oncology Ltd., Chong Kun Dang Pharmaceutical.

Intelligence

Pipeline Metrics

Competitive Density

24/100

Pipeline Velocity

6/100

Mech. Concentration

100/100

Completion Rate

64/100

Attrition Rate

26/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

T

Treadwell Therapeutics, Inc

1 program

Phase 1F

Fresenius Kabi Oncology Ltd.

1 program

Phase 1Chong Kun Dang Pharmaceutical logo

Chong Kun Dang Pharmaceutical

0 programs

PreclinicalBristol-Myers Squibb logo

Bristol-Myers Squibb

0 programs

PreclinicalJohnson & Johnson logo

Johnson & Johnson

0 programs

PreclinicalS

Shenzhen NewDEL Biotech, Co., Ltd

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 12

CFI-402257

Treadwell Therapeutics, Inc

Fulvestrant

Fresenius Kabi Oncology Ltd.

Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Trial Status

19

clinical trials

Completed9 · 47%
Terminated5 · 26%
Recruiting2 · 11%
Enrolling by invitation1 · 5%
Unknown status1 · 5%
Active, not recruiting1 · 5%

Clinical Trials

Trial Activity

19 trials

Testing How the Body Responds to the Drug CBX-12 in Patients With Advanced Solid Cancers
Recruiting·National Cancer Institute (NCI)·Phase 1·NCT05691517·35 enrolled
Exploratory Clinical Study of Targeted Activated DC and CAR-T Therapy in Advanced Solid Cancers
Recruiting·HHainan Cancer Hospital·Phase 1·NCT07475182·10 enrolled
Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN
Active, not recruiting·National Cancer Institute (NCI)·Phase 1/2·NCT04317105·54 enrolled
An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of ND-003 in Patients With Advanced Solid Cancers
Enrolling by invitation·SShenzhen NewDEL Biotech, Co., Ltd·Phase 1·NCT06169579·96 enrolled
An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers
Completed·HHenlix, Inc·Phase 1·NCT02648490·19 enrolled
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-Programmed Cell Death (PD)-1 Monoclonal Antibody, as Monotherapy or in Combination With Erdafitinib in Japanese Participants With Advanced Solid Cancers
Completed·Johnson & Johnson logoJohnson & Johnson·Phase 1·NCT03547037·22 enrolled
Safety Study of Increasing Doses of CKD-516 in Patients With Advanced Solid Cancers
Completed·Chong Kun Dang Pharmaceutical logoChong Kun Dang Pharmaceutical·Phase 1·NCT01560325·21 enrolled
Pembrolizumab Before Surgery for the Treatment of Mismatch Repair Deficient Locally Advanced Solid Cancers
Completed·MM.D. Anderson Cancer Center·Phase 2·NCT04082572·35 enrolled
Neratinib and Trastuzumab Biosimilar in Patients with HER2 Mutated Advanced Solid Cancers
Completed·KKorea University Guro Hospital·Phase 2·NCT06083662·42 enrolled
An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers
Completed·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 1·NCT03956680·54 enrolled
Safety Study of Increasing Doses of CKD-516 in Patients With Advanced Solid Cancers
Completed·Chong Kun Dang Pharmaceutical logoChong Kun Dang Pharmaceutical·Phase 1·NCT01028859·30 enrolled
An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers
Completed·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 1/2·NCT03994601·219 enrolled
An Open Label, Dose Escalation, Safety, and Pharmacokinetic Study of CFI-402257 Administered Orally to Patients With Advanced Solid Tumors
Completed·UUniversity Health Network, Toronto·Phase 1·NCT02792465·52 enrolled
A Study of the mTOR Inhibitor Rapamycin (Rapamune, Sirolimus) in Combination With Abraxane in Advanced Solid Cancers
Terminated·YYale University·Phase 1·NCT00337376·23 enrolled
Talabostat and Pembrolizumab for the Treatment of Advanced Solid Cancers
Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT04171219·31 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)